[go: up one dir, main page]

ES2517190A1 - Canine mammary inflammatory carcinoma cell line - Google Patents

Canine mammary inflammatory carcinoma cell line Download PDF

Info

Publication number
ES2517190A1
ES2517190A1 ES201400512A ES201400512A ES2517190A1 ES 2517190 A1 ES2517190 A1 ES 2517190A1 ES 201400512 A ES201400512 A ES 201400512A ES 201400512 A ES201400512 A ES 201400512A ES 2517190 A1 ES2517190 A1 ES 2517190A1
Authority
ES
Spain
Prior art keywords
cell line
inflammatory carcinoma
canine
mammary
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201400512A
Other languages
Spanish (es)
Other versions
ES2517190B2 (en
Inventor
Juan Carlos ILLERA DEL PORTAL
Laura PEÑA FERNÁNDEZ
Sara CÁCERES RAMOS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Complutense de Madrid
Original Assignee
Universidad Complutense de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Complutense de Madrid filed Critical Universidad Complutense de Madrid
Priority to ES201400512A priority Critical patent/ES2517190B2/en
Publication of ES2517190A1 publication Critical patent/ES2517190A1/en
Application granted granted Critical
Publication of ES2517190B2 publication Critical patent/ES2517190B2/en
Priority to PCT/ES2015/000080 priority patent/WO2015197884A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • C12N5/063—Kereatinocyte stem cells; Keratinocyte progenitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Línea celular de carcinoma inflamatorio mamario canino. La presente invención se refiere a una línea celular establecida de carcinoma inflamatorio mamario canino, de células epiteliales basales triple negativas. La invención también se refiere a un método para la obtención de xenotransplantes estables de carcinoma inflamatorio mamario canino en animales de experimentación, y al uso de la línea celular y de los xenotransplantes en el estudio del carcinoma inflamatorio mamario canino así como del carcinoma inflamatorio mamario humano y su uso para identificar in vitro compuestos terapéuticamente útiles para el tratamiento del cáncer inflamatorio mamario humano. También se refiere a un kit para el estudio in vitro de IMC canino y/o IBC humano y de fármacos potencialmente utilizables frente al IBC humano, que incluye la línea celular de la invención.Canine mammary inflammatory carcinoma cell line. The present invention relates to an established triple-negative basal epithelial cell line of canine mammary inflammatory carcinoma. The invention also refers to a method for obtaining stable xenografts of canine mammary inflammatory carcinoma in experimental animals, and to the use of the cell line and of the xenografts in the study of canine mammary inflammatory carcinoma as well as human mammary inflammatory carcinoma. and its use to identify therapeutically useful compounds in vitro for the treatment of human inflammatory breast cancer. It also refers to a kit for the in vitro study of canine BMI and/or human IBC and potentially usable drugs against human IBC, which includes the cell line of the invention.

Description

imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

imagen7image7

imagen8image8

imagen9image9

imagen10image10

imagen11image11

imagen12image12

imagen13image13

imagen14image14

imagen15image15

Claims (1)

imagen1image 1
ES201400512A 2014-06-27 2014-06-27 Canine mammary inflammatory carcinoma cell line Active ES2517190B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201400512A ES2517190B2 (en) 2014-06-27 2014-06-27 Canine mammary inflammatory carcinoma cell line
PCT/ES2015/000080 WO2015197884A1 (en) 2014-06-27 2015-06-19 Cell line of canine inflammatory mammary carcinoma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201400512A ES2517190B2 (en) 2014-06-27 2014-06-27 Canine mammary inflammatory carcinoma cell line

Publications (2)

Publication Number Publication Date
ES2517190A1 true ES2517190A1 (en) 2014-10-31
ES2517190B2 ES2517190B2 (en) 2015-05-05

Family

ID=51795084

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201400512A Active ES2517190B2 (en) 2014-06-27 2014-06-27 Canine mammary inflammatory carcinoma cell line

Country Status (2)

Country Link
ES (1) ES2517190B2 (en)
WO (1) WO2015197884A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113980904B (en) * 2021-11-25 2023-11-28 华中农业大学 A kind of canine inflammatory breast cancer cell line and its application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110085982A1 (en) * 2009-10-09 2011-04-14 Duke University; The Regents of the University of California Dkat cell line, a model for human triple-negative breast cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110085982A1 (en) * 2009-10-09 2011-04-14 Duke University; The Regents of the University of California Dkat cell line, a model for human triple-negative breast cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FERNANDEZ S. V., et al. Inflammatory breast cancer (IBC): clues for targeted therapies. Breast cancer research and treatment Netherlands Jul 2013 VOL: 140 No: 1 Pags: 23 - 33 ISSN 1573-7217 (Electrónico) Doi: doi:10.1007/s10549-013-2600-4 pubmed:23784380. Ver todo el documento. *
KIM N. H., et al. Identification of triple-negative and basal-like canine mammary carcinomas using four basal markers. Journal of comparative pathology England May 2013 VOL: 148 No: 4 Pags: 298 - 306 ISSN 1532-3129 (Electrónico) Doi: doi:10.1016/j.jcpa.2012.08.009 pubmed:23079102. Ver todo el documento. *
PINHO S. S., et al. Canine tumors: a spontaneous animal model of human carcinogenesis. Translational research : the journal of laboratory and clinical medicine United States Mar 2012 VOL: 159 No: 3 Pags: 165 - 172 ISSN 1878-1810 (Electrónico) Doi: doi:10.1016/j.trsl.2011.11.005 pubmed:22340765. Ver todo el documento. *

Also Published As

Publication number Publication date
ES2517190B2 (en) 2015-05-05
WO2015197884A1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
CL2015003395A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MX2018001721A (en) 5-BROMO-2,6-DI- (1H-PIRAZOL-1-IL) PIRIMIDIN-4-AMINA-FOR USE IN THE TREATMENT OF CANCER.
MX2021005561A (en) RAD1901 FOR USE IN THE TREATMENT OF CANCER IN SUBJECTS WITH DRUG-RESISTANT ESTROGEN RECEPTOR ALPHA-POSITIVE CANCER.
NI201700034A (en) INDAZOLES SUBSTITUTED WITH BENZYL AS BUB1 INHIBITORS.
MX2016012097A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer.
CL2015002194A1 (en) Erk inhibitors and their uses
UY36738A (en) TGR5 MODULATORS AND SAME USE METHODS
MX2017006785A (en) METHODS AND COMPOSITIONS FOR RADIO LABELING WITH 18F OF BIOLOGICAL PRODUCTS.
MX2017014375A (en) Ccr2 modulators.
CL2016001609A1 (en) Pharmaceutical compositions comprising azd9291.
MX377340B (en) SOLID SOLUTION COMPOSITIONS AND USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES.
CL2017000053A1 (en) Β-protofibril binding antibodies
MX2018004050A (en) INHIBITORS MARKED WITH 18F IMPROVED THE MEMBRANE SPECIFIC ANTIGEN (PSMA) AND ITS USE AS IMAGE FORMATION AGENTS FOR PROSTATA CANCER.
CR20170076A (en) PIRIMIDIMA DERIVATIVES REPLACED WITH OPTIONALLY CONDENSED HETEROCICLYL USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGICAL AND SELF-IMMUNITY DISEASES
MX380252B (en) CRENEZUMAB FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE.
ECSP14017586A (en) TETRAHYDRO-QUINAZOLINONE DERIVATIVES
CO2017000552A2 (en) Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
HUE047540T2 (en) Improved allogeneic dendritic cells for use in the treatment of cancer
CL2016001937A1 (en) Functionalized benzopyran compounds and their use
NI201500175A (en) NEW COMPOUNDS FOR THE TREATMENT OF CANCER
MX2017009294A (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide.
MX2018005987A (en) HETEROCICLICAL COMPOUNDS FOR THE TREATMENT OF DISEASES.
ECSP16086247A (en) (S) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
ECSP16086232A (en) (R) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
ES2565198T3 (en) Avian metapneumovirus in oncolysis

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2517190

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20150505